Sanofi (EPA:SAN)

Revenue

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Dupixent Revenue	16.40B	15.71B	13.07B
Dupixent Revenue Growth	4.39%	20.21%	22.00%
Pharma Revenue	36.34B	35.69B	32.78B
Pharma Revenue Growth	1.82%	8.87%	-
Total Vaccine Revenue	7.90B	7.94B	8.30B
Total Vaccine Revenue Growth	-0.43%	-4.36%	11.03%
BioPharma Revenue	44.24B	43.63B	41.08B
BioPharma Revenue Growth	1.41%	6.19%	8.63%
Revenue (Other)	-13.29B	-12.62B	-9.87B
Revenue (Total)	47.35B	46.72B	44.29B
Revenue (Total) Growth	1.37%	5.49%	6.41%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	22.81B	22.18B	19.99B
United States Revenue Growth	2.85%	10.96%	7.96%
Europe Revenue	9.29B	9.17B	9.03B
Europe Revenue Growth	1.31%	1.57%	-13.13%
Rest of World Revenue	12.14B	12.28B	12.07B
Rest of World Revenue Growth	-1.12%	1.76%	-14.81%
Revenue (Other)	3.11B	3.09B	3.21B
Revenue (Total)	47.35B	46.72B	44.29B
Revenue (Total) Growth	1.37%	5.49%	6.41%

EBIT

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Biopharma Operating Income	12.19B	12.12B	11.29B
Biopharma Operating Income Growth	0.51%	7.43%	1.17%
Other (Post-2022 Reporting) Operating Income	29.00M	26.00M	58.00M
Other (Post-2022 Reporting) Operating Income Growth	11.54%	-55.17%	152.17%
Operating Income (Total)	6.18B	6.34B	7.25B
Operating Income (Total) Growth	-2.60%	-12.52%	4.20%

Data Source: Fiscal.ai Last updated: Mar 31, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 29, 2026

Data Sources Report a data error